As of January 1, 2026, a new legal framework has come into effect in the Czech Republic allowing the limited therapeutic use of psilocybin in patients with severe mental health conditions. This represents the first systematic step in translating the results of long-term clinical research on psychedelics into healthcare practice. How does this change clinical practice, and what should physicians know even if they do not provide this therapy themselves?
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
